Details
Description
In this analysis, we identified incident users of clozapine in the pre-Risk Evaluation and Mitigation Strategies (REMS) (1/1/10-9/30/15), post-REMS (10/1/15-12/31/19), and COVID-REMS (1/1/20-7/31/23) time periods in the Sentinel Distributed Database (SDD). Among these new use episodes, we present information on absolute neutrophil count (ANC) procedures and laboratory results as well as diagnoses of neutropenia.
We distributed this request to 13 Sentinel Data Partners on March 11, 2024. The study period includes data from January 1, 2010 to March 31, 2024. This analysis contains two reports.
- Report 1 includes data from ten Data Partners (a subset of the SDD) that include ANC laboratory results in the Laboratory Results table within their Sentinel Common Data Model (SCDM) and does not include data from patients with Medicare.
- Report 2 contains data from all 13 Data Partners, regardless of ANC presence.
Deliverables (2)
Sentinel Modular Program Report: Occurrence of Absolute Neutrophil Count (ANC) Monitoring, ANC Laboratory Results, and Neutropenia Following Clozapine Use: A Descriptive Analysis, Report 1
Sentinel Modular Program Report: Occurrence of Absolute Neutrophil Count (ANC) Monitoring, ANC Laboratory Results, and Neutropenia Following Clozapine Use: A Descriptive Analysis, Report 2